Evidence map›Paper›PMID 39899354›Full record

ArticleAIDS research and human retroviruses2025

Transient Viremia Among People with HIV Receiving Injectable Cabotegravir Plus Rilpivirine.

Lauren F O'Connor, Wei Li Adeline Koay, Justin Unternaher, Morgan Byrne, Anne K Monroe, Alan Greenberg, Amanda D Castel, Natella Rakhmanina, DC Cohort Executive Committee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lauren F O'ConnorMilken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.ORCID 0000-0002-9205-0544
Wei Li Adeline KoayDivision of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
Justin UnternaherDivision of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
Morgan ByrneMilken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
Anne K MonroeMilken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.ORCID 0000-0003-3201-3845
Alan GreenbergMilken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.ORCID 0000-0003-1674-0217
Amanda D CastelMilken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
Natella RakhmaninaDivision of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
DC Cohort Executive Committee

Funding

The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living with HIV in Washington, DCR24AI152598 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Amanda Derryck Castel, Marinella Temprosa · 2020 to 2026
$37.9M
NIAID NIH HHS R24 AI152598
6 · The paper itself

Abstract

Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides an effective treatment option for people with HIV (PWH). Studies suggest that PWH on LAI CAB/RPV may experience isolated episodes of transient viremia (HIV RNA > 20 copies/mL) defined as virologic blips (VB). The risk factors for VB in PWH receiving LAI CAB/RPV are limited. We aimed to describe a cohort of PWH on LAI CAB/RPV and evaluate risk factors and time to VB following LAI CAB/RPV initiation. We obtained DC Cohort data from PWH who initiated LAI CAB/RPV prior to July 2023 and used Kaplan-Meier curves and Cox proportional hazards models to evaluate the association between participant demographics, HIV clinical factors, and time to VB. Among 98 PWH who initiated LAI CAB/RPV, 9 (9.2%) experienced at least one VB (median HIV RNA = 50 copies/mL; ranges 30-12,000 copies/mL) during a median follow-up period of five months (IQR: 2-10). The median CD4 count among PWH was 754 cells/µL (IQR: 598, 980) at the time of LAI CAB/RPV initiation. Having a high CD4 (≥ 500 cells/μL) at LAI CAB/RPV initiation was significantly associated with a lower hazard for VB when compared to baseline CD4 < 200 cells/µL [hazard ratios (HR): 0.15 [95% confidence intervals (CI): 0.03, 0.77]; aHR: 0.07 (95% CI: 0.01, 0.50); log-rank

Indexed as

Anti-HIV AgentsHIV InfectionsPyridonesRilpivirineViremiaAdultCD4 Lymphocyte CountCohort StudiesDiketopiperazinesFemaleHumansMaleMiddle AgedRisk FactorsRNA, ViralViral LoadAnti-HIV AgentscabotegravirDiketopiperazinesPyridonesRilpivirineRNA, Viralcabotegravir-rilpivirineHIVinjectablelong-actingviremia

Identifiers

PMID39899354
PMCPMC12344116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.